

Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced *RET* fusion+ non-small cell lung cancer (NSCLC)

Benjamin Besse,¹ Frank Griesinger,² Giuseppe Curigliano,³ Michael Thomas,⁴ Vivek Subbiah,⁵ Christina S. Baik,⁶ Daniel S.W. Tan,⁷ Dae Ho Lee,⁸ Elena Garralda,⁹ Dong-Wan Kim,¹⁰ Anthonie J. van der Wekken,¹¹ Justin F. Gainor,¹² Luis Paz-Ares,¹³ Stephen V. Liu,¹⁴ Daniel W. Bowles,¹⁵ Alena Zalutskaya,¹⁶ Thorsten Ruf,¹⁷ Ahmadur Rahman,¹⁸ Geng Chen,¹⁹ Julien Mazieres²⁰

¹Department of Cancer Medicine, Gustave Roussy Cancer Centre, Villejuif, France; ²Department of Hematology and Oncology, Internal Medicine-Oncology, Pius-Hospital, University of Oldenburg, Oldenburg, Germany; ³European Institute of Oncology, IRCCS and Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy; ⁴Department of Thoracic Oncology, Thoraxklinik, University Heidelberg and Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany; ⁵Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁶Department of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA; ⁷Division of Medical Oncology, National Cancer Centre Singapore, Singapore; ⁸Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; ⁹Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain; ¹⁰Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea; ¹¹Department of Pulmonology and Tuberculosis, University of Groningen and University Medical Center Groningen, Groningen, Netherlands; ¹²Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; ¹³Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; ¹⁴Department of Medicine, Georgetown University, Washington, DC, USA; ¹⁵Department of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, USA; ¹⁶Clinical Development, Oncology, Blueprint Medicines Corporation, Cambridge, MA, USA; ¹⁷Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland; ¹⁸Product Development, F. Hoffmann-La Roche Ltd, Welwyn, UK; ¹⁹Data and Statistical Sciences, Genentech Inc., South San Francisco, CA, USA; ²⁰Thoracic Oncology Department, Institut Universitaire du Cancer, Toulouse, France

BACKGROUND

- Pralsetinib is approved by the FDA and EMA for the treatment of advanced *RET* fusion-positive NSCLC^{1,2} based on the global multicohort, open-label, phase I/II ARROW study (NCT03037385)³
- Prior results from ARROW show that pralsetinib has promising anti-tumour activity with a manageable safety profile in advanced *RET* fusion-positive NSCLC³
- Here, we present updated data from the *RET* fusion-positive NSCLC cohort after an additional 16 months of follow-up since the previous analysis

METHODS

- Phase I of ARROW established the recommended phase II dose of pralsetinib as 400 mg once daily
- In the *RET* fusion-positive NSCLC cohort, patients aged ≥18 years with ECOG PS 0–2 (limited to 0–1 after a protocol amendment) and locally documented *RET* fusions received pralsetinib until disease progression, intolerance or withdrawal
- Prior to 11 July 2019, only treatment-naïve patients who were not candidates for standard platinum-based chemotherapy as determined by the investigator were eligible for enrolment; the eligibility criteria were expanded to include all treatment-naïve patients (both patients eligible and ineligible for standard systemic therapy)
- Primary endpoints in phase II were overall response rate (ORR); blinded independent central review [BICR] per RECIST v1.1) and safety
- Key secondary endpoints in phase II were duration of response (DOR), clinical benefit rate (CBR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS)

Disclosures

Benjamin Besse (email address: Benjamin.BESSE@gustaveroussy.fr) reports research grants to his institution from 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergents, Chugai Pharmaceutical, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, Eisai, Genzyme Corporation, GSK, Inivata, IPSEN, Janssen, Onxeo, OSE Immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals and Turning Point Therapeutics. For co-author disclosures, please refer to the abstract: <https://oncologypro.esmo.org>

RESULTS

- At the updated data cut-off of 4 March 2022, 281 patients with *RET* fusion-positive NSCLC had received pralsetinib 400 mg (efficacy population), of whom 260 had measurable disease at baseline per BICR (measurable disease population)

Table 1. Baseline characteristics

n (%)	Measurable disease population			Efficacy population		
	All (n=260)	Treatment naïve (n=107)	Prior platinum treatment (n=130)	All (n=281)	Treatment naïve (n=116)	Prior platinum treatment (n=141)
Age, years						
<65 years	164 (63.1)	64 (59.8)	85 (65.4)	176 (62.6)	67 (57.8)	93 (66.0)
Male	121 (46.5)	50 (46.7)	64 (49.2)	129 (45.9)	55 (47.4)	67 (47.5)
Race						
White	119 (45.8)	52 (48.6)	52 (40.0)	130 (46.3)	57 (49.1)	57 (40.4)
Asian	118 (45.4)	48 (44.9)	65 (50.0)	128 (45.6)	52 (44.8)	71 (50.4)
Other	23 (8.8)	7 (6.5)	13 (10.0)	2 (0.7)	0	2 (1.4)
Smoking history						
Current/former	95 (36.5)	44 (41.1)	47 (36.2)	100 (35.6)	45 (38.8)	50 (35.5)
Never	161 (61.9)	61 (57.0)	81 (62.3)	176 (62.6)	68 (58.6)	89 (63.1)
Unknown	4 (1.5)	2 (1.9)	2 (1.5)	5 (1.8)	3 (2.6)	2 (1.4)
ECOG PS						
0	78 (30.0)	33 (30.8)	34 (26.2)	83 (29.5)	35 (30.2)	37 (26.2)
1	175 (67.3)	73 (68.2)	90 (69.2)	191 (68.0)	80 (69.0)	98 (69.5)
2	6 (2.3)	1 (<1)	5 (3.8)	6 (2.1)	1 (<1)	5 (3.5)
Brain metastases	91 (35.0)	30 (28.0)	53 (40.8)	97 (34.5)	34 (29.3)	55 (39.0)
Prior therapy type						
Platinum-based	130 (50.0)	0	130 (100)	141 (50.2)	0	141 (100)
Multikinase inhibitor	41 (15.8)	0	35 (26.9)	45 (16.0)	0	39 (27.7)
PD-(L)1 inhibitor	69 (26.5)	0	54 (41.5)	73 (26.0)	0	57 (40.4)
<i>RET</i> fusion						
KIF5B	184 (70.8)	76 (71.0)	91 (70.0)	197 (70.1)	81 (69.8)	98 (69.5)
CCDC6	48 (18.5)	19 (17.8)	25 (19.2)	50 (17.8)	19 (16.4)	27 (19.1)
NCOA4	1 (<1)	0	1 (<1)	2 (<1)	1 (<1)	1 (<1)
Other	27 (10.4)	12 (11.2)	13 (10.0)	32 (11.4)	15 (12.9)	15 (10.6)

PD-(L)1, programmed cell death protein-1 or programmed cell death ligand-1.

Table 2. Efficacy summary

	Measurable disease population				Efficacy population			
	All (n=260)	Treatment naïve		Prior platinum treatment (n=130)	All (n=281)	Treatment naïve		Prior platinum treatment (n=141)
Pre-eligibility revision (n=43)		Post eligibility revision (n=64)	Pre-eligibility revision (n=47)			Post eligibility revision (n=69)		
ORR, % (95% CI)	70.0 (64.0–75.5)	74.4 (58.8–86.5)	79.7 (67.8–88.7)	63.1 (54.2–71.4)	65.8 (60.0–71.4)	68.1 (52.9–80.9)	75.4 (63.5–84.9)	59.6 (51.0–67.7)
Complete response, n (%)	15 (5.8)	4 (9.3)	3 (4.7)	8 (6.2)	18 (6.4)	4 (8.5)	4 (5.8)	10 (7.1)
Partial response, n (%)	167 (64.2)	28 (65.1)	48 (75.0)	74 (56.9)	167 (59.4)	28 (59.6)	48 (69.6)	74 (52.5)
CBR, % (95% CI)	77.3 (71.7–82.3)	79.1 (64.0–90.0)	81.3 (69.5–89.9)	74.6 (66.2–81.8)	77.2 (71.9–82.0)	74.5 (59.7–86.1)	82.6 (71.6–90.7)	75.2 (67.2–82.1)
DCR, % (95% CI)	91.2 (87.0–94.3)	90.7 (77.9–97.4)	90.6 (80.7–96.5)	91.5 (85.4–95.7)	90.4 (86.3–93.6)	87.2 (74.3–95.2)	91.3 (82.0–96.7)	90.8 (84.7–95.0)
	n=182	n=32	n=51	n=82	n=185	n=32	n=52	n=84
Median DOR, months (95% CI)^a	19.1 (14.5–27.9)	14.7 (7.4–27.9)	12.6 (9.4–NR)	38.8 (14.8–40.4)	19.1 (14.5–27.3)	14.7 (7.4–27.9)	13.4 (9.4–NR)	23.4 (14.8–39.4)
Median follow-up (95% CI)	23.9 (21.4–27.6)	27.6 (21.2–30.2)	17.4 (14.3–20.3)	29.3 (24.1–33.1)	24.1 (21.6–27.6)	27.6 (21.2–30.2)	17.4 (14.3–20.3)	31.4 (25.3–33.1)
Median PFS, months (95% CI)^b	13.1 (11.0–16.7)	11.0 (9.0–24.9)	12.6 (9.2–21.1)	14.5 (10.5–22.1)	13.2 (11.4–16.8)	10.9 (7.7–20.1)	13.2 (9.2–21.1)	16.4 (11.4–22.3)
Median follow-up (95% CI)	26.1 (23.8–28.1)	29.0 (18.2–34.7)	19.7 (15.9–22.1)	29.3 (26.6–34.9)	25.8 (23.8–27.7)	29.0 (16.6–34.7)	19.7 (15.9–22.1)	28.1 (26.1–34.9)

The measurable disease population was the primary population for analysis of ORR, CBR, DCR and DOR and the efficacy population was the primary population for analysis of PFS and OS. ^aDOR for the measurable disease population per FDA censoring rule and DOR for the efficacy population per EMA censoring rule; ^bPFS for the measurable disease and efficacy populations per FDA censoring rule. CI, confidence interval; NR, not reached.

Acknowledgements

This study was sponsored by F. Hoffmann-La Roche Ltd. Third party medical writing assistance, under the direction of the authors, was provided by Fiona Duthie, PhD, of Ashfield MedComms, an Inizio Company, and was funded by F. Hoffmann-La Roche Ltd.

References

1. FDA. Pralsetinib Prescribing Information 2022
2. EMA. Pralsetinib Summary of Product Characteristics 2022
3. Gainor JF, et al. *Lancet Oncol* 2021;22:959–69.

Figure 1. PFS^a (A) and OS (B) in the efficacy population




Table 3. CNS efficacy

	All (n=15)
CNS ORR, % (95% CI)	53.3 (26.6–78.7)
Complete response, n (%)	3 (20.0)
Partial response, n (%)	5 (33.3)
	n=8
Median DOR, months (95% CI)^a	11.5 (9.2–NR)
Median follow-up (95% CI)	29.7 (24.1–35.3)

Of the 15 patients, 14 had prior platinum treatment and 1 was treatment naïve. ^aPer EMA censoring rule.

Safety

- In the safety population (n=281), median treatment duration was 15.0 months with a median relative dose intensity of 86.1%
- Overall, 10% of patients discontinued pralsetinib due to treatment-related adverse events (TRAEs)

Table 4. Safety summary

n=281, n (%)	Any causality		Treatment related	
	Any grade	Grade ≥3	Any grade	Grade ≥3
Patients with any AE	280 (99.6)	231 (82.2)	265 (94.3)	176 (62.6)
Anaemia	151 (53.7)	65 (23.1)	119 (42.3)	55 (19.6)
AST increased	137 (48.8)	18 (6.4)	125 (44.5)	11 (3.9)
Constipation	125 (44.5)	2 (<1)	76 (27.0)	2 (<1)
Hypertension	103 (36.7)	50 (17.8)	75 (26.7)	39 (13.9)
ALT increased	101 (35.9)	13 (4.6)	92 (32.7)	9 (3.2)
Neutrophil count decreased	88 (31.3)	40 (14.2)	87 (31.0)	37 (13.2)
Diarrhoea	84 (29.9)	7 (2.5)	50 (17.8)	3 (1.1)
Cough	81 (28.8)	1 (<1)	15 (5.3)	1 (<1)
Pyrexia	81 (28.8)	2 (<1)	22 (7.8)	0
White blood cell count decreased	77 (27.4)	16 (5.7)	74 (26.3)	15 (5.3)
Fatigue	75 (26.7)	6 (2.1)	46 (16.4)	5 (1.8)
Blood creatinine increased	70 (24.9)	2 (<1)	48 (17.1)	1 (<1)
Neutropenia	64 (22.8)	30 (10.7)	60 (21.4)	26 (9.3)
Dyspnoea	62 (22.1)	8 (2.8)	5 (1.8)	1 (<1)
Pneumonia	56 (19.9)	36 (12.8)	18 (6.4)	12 (4.3)

The table includes AEs which occurred in ≥20% of patients.

AE, adverse event; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Table 5. TRAEs by history of immune checkpoint inhibitor treatment

n=281, n (%)	Any grade		Grade ≥3	
	Prior PD-(L)1 treatment (n=73)	Treatment naïve (n=116)	Prior PD-(L)1 treatment (n=73)	Treatment naïve (n=116)
Neutropenia	33 (45.2)	55 (47.4)	14 (19.2)	22 (19.0)
Anaemia	30 (41.1)	54 (46.6)	15 (20.5)	25 (21.6)
AST increased	28 (38.4)	51 (44.0)	4 (5.5)	3 (2.6)
Leukopenia	25 (34.2)	50 (43.1)	7 (9.6)	10 (8.6)
ALT increased	22 (30.1)	41 (35.3)	4 (5.5)	2 (1.7)
Hypertension	22 (30.1)	28 (24.1)	8 (11.0)	16 (13.8)
Fatigue	21 (28.8)	35 (30.2)	2 (2.7)	1 (<1)
Blood creatinine increased	18 (24.7)	18 (15.5)	0	1 (<1)
Constipation	15 (20.5)	36 (31.0)	1 (1.4)	0

The table includes grouped AE terms which occurred in ≥20% of patients.

CONCLUSIONS

With additional follow-up, pralsetinib demonstrated robust and durable clinical activity in patients with advanced *RET* fusion-positive NSCLC, including systemic treatment-naïve patients.

No new or unexpected safety findings emerged from this updated data cut with a low discontinuation rate due to TRAEs.



Copies of this poster obtained through QR (Quick Response) and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.

Visit [Medically.Roche.com](https://www.Medicinally.Roche.com) for more information.